Cervarix shows superior immune response to Gardasil in Phase III
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's cervical cancer vaccine Cervarix has shown a superior immune response to Merck & Co's Gardasil in the first large-scale head-to-head trial of the two rival vaccines, which could potentially mean that Cervarix offers longer lasting protection against cervical cancer.